Difference between revisions of "NK- and T-cell lymphoma - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
−
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[NK- and T-cell lymphoma|main NKTCL page]] for current regimens.
+
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[NK- and T-cell lymphoma|main NKTCL page]] for current regimens.
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 10: Line 10:
 
<div class="toccolours" style="background-color:#ee6b6e">
 
<div class="toccolours" style="background-color:#ee6b6e">
 
===Regimen {{#subobject:ga3na4|Variant=1}}===
 
===Regimen {{#subobject:ga3na4|Variant=1}}===
−
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
−
!style="width: 25%"|Study
+
!style="width: 33%"|Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://doi.org/10.1182/blood-2016-12-756841 Kwong et al. 2017]
 
|[https://doi.org/10.1182/blood-2016-12-756841 Kwong et al. 2017]
 +
|NR
 
| style="background-color:#ffffbe" |Case series
 
| style="background-color:#ffffbe" |Case series
 
|-
 
|-
Line 24: Line 26:
 
'''21-day cycles'''
 
'''21-day cycles'''
 
</div></div>
 
</div></div>
 +
 
===References===
 
===References===
 
#Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. [https://doi.org/10.1182/blood-2016-12-756841 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28188133/ PubMed]
 
#Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. [https://doi.org/10.1182/blood-2016-12-756841 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28188133/ PubMed]

Latest revision as of 18:11, 2 July 2024

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main NKTCL page for current regimens.

1 regimens on this page
1 variants on this page


Relapsed or refractory

Pembrolizumab monotherapy

Regimen

Study Dates of enrollment Evidence
Kwong et al. 2017 NR Case series

Note: prospective trials are underway.

Immunotherapy

21-day cycles

References

  1. Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=NK-_and_T-cell_lymphoma_-_historical&oldid=87988"